Factors Determining the Switch of the First Biological Treatment in Spondyloarthritis: Data from the RBSMR Registry

The new bio-medications have considerably improved the prognosis of patients suffering from chronic inflammatory rheumatism, necessitating regular monitoring to detect events that could lead to a treatment switch. In our study, we identified factors associated with therapeutic switching, particularly advanced age, a history of corticosteroid therapy, and specific comorbidities. These findings highlight potential risk factors; however, further studies with larger cohorts and immunogenicity data are required before firm clinical recommendations can be made.